Esperion Therapeutics Inc (NAS:ESPR)
$ 2.08 -0.03 (-1.41%) Market Cap: 394.08 Mil Enterprise Value: 445.93 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Esperion Therapeutics Inc at Morgan Stanley Life After Covid Thematic Conference (Virtual) Transcript

May 20, 2021 / 03:15PM GMT
Release Date Price: $20.48 (+0.15%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

Welcome to the Morgan Stanley Life after COVID: 2021 Thematic Conference. I'm Jeff Hung, the biotech analysts.

Before we start, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

For this session, we have Sheldon Koenig, CEO of Esperion. Welcome, Sheldon.

Sheldon L. Koenig
Esperion Therapeutics, Inc. - President, CEO & Director

Jeff, thanks for having me.

Questions & Answers

Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

Thank you. For those who may not be familiar with Esperion, can you provide a brief introduction?

Sheldon L. Koenig
Esperion Therapeutics, Inc. - President, CEO & Director

Absolutely.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot